A phase I/II open label study of IPH1101 (with low dose of interleukin-2 [IL-2]) in combination with rituximab re-treatment in patients with Follicular Lymphoma

Update Il y a 4 ans
Reference: EUCTR2006-006891-39

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective of this study is to assess the clinical efficacy of IPH1101 (with low-dose IL 2, as aldesleukin), administered in combination with a standard course of rituximab, in patients with Follicular Lymphoma having relapsed after at least one prior rituximab-containing line.


Inclusion criteria

  • Follicular lymphoma